Paths of FGFR-driven tumorigenesis

被引:132
作者
Acevedo, Victor D. [1 ,2 ]
Ittmann, Michael [3 ]
Spencer, David M. [1 ,2 ]
机构
[1] Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
关键词
prostate cancer; fibroblast growth factor receptor (FGFR); chemical inducer of dimerization (CID); epithelial-mesenchymal transition (EMT); angiogenesis; androgen independence; FIBROBLAST-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR TYROSINE KINASE; PROSTATE-CANCER; ANDROGEN-RECEPTOR; TUMOR-GROWTH; ENDOTHELIAL-CELLS; INTRAEPITHELIAL NEOPLASIA; TRANSCRIPTION FACTOR; STRUCTURAL BASIS;
D O I
10.4161/cc.8.4.7657
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Fibroblast growth factor receptors (FGFRs) comprise a subfamily of receptor tyrosine kinases (RTKs) that are master regulators of a broad spectrum of cellular and developmental processes, including apoptosis, proliferation, migration and angiogenesis. Due to their broad impact, FGFRs and other RTKs are highly regulated and normally only basally active. Deregulation of FGFR signaling by activating mutations or ligand/receptor overexpression could allow these receptors to become constitutively active, leading to cancer development, including both hematopoietic and solid tumors, such as breast, bladder and prostate carcinomas. In this review, we focus on potential modes of FGFR-mediated tumorigenesis, in particular, the role of FGFR1 during prostate cancer progression.
引用
收藏
页码:580 / 588
页数:9
相关论文
共 123 条
  • [41] HORI A, 1991, CANCER RES, V51, P6180
  • [42] Molecular requirements for epithelial-mesenchymal transition during tumor progression
    Huber, MA
    Kraut, N
    Beug, H
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2005, 17 (05) : 548 - 558
  • [43] Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression
    Huss, WJ
    Barrios, RJ
    Foster, BA
    Greenberg, NM
    [J]. PROSTATE, 2003, 54 (01) : 8 - 16
  • [44] Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development
    Jiao, Jing
    Wang, Shunyou
    Qiao, Rong
    Vivanco, Igor
    Watson, Philip A.
    Sawyers, Charles L.
    Wu, Hong
    [J]. CANCER RESEARCH, 2007, 67 (13) : 6083 - 6091
  • [45] Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors
    Jin, CL
    Wang, F
    Wu, XC
    Yu, CD
    Luo, YD
    McKeehan, WL
    [J]. CANCER RESEARCH, 2004, 64 (13) : 4555 - 4562
  • [46] Modulation of signalling by sprouty: A developing story
    Kim, HJ
    Bar-Sagi, D
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (06) : 441 - 450
  • [47] A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway
    Kouhara, H
    Hadari, YR
    SpivakKroizman, T
    Schilling, J
    BarSagi, D
    Lax, I
    Schlessinger, J
    [J]. CELL, 1997, 89 (05) : 693 - 702
  • [48] Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity
    Kousteni, S
    Bellido, T
    Plotkin, LI
    O'Brien, CA
    Bodenner, DL
    Han, L
    Han, K
    DiGregorio, GB
    Katzenellenbogen, JA
    Katzenellenbogen, BS
    Roberson, PK
    Weinstein, RS
    Jilka, RL
    Manolagas, SC
    [J]. CELL, 2001, 104 (05) : 719 - 730
  • [49] The role of fibroblast growth factors and their receptors in prostate cancer
    Kwabi-Addo, B
    Ozen, M
    Ittmann, M
    [J]. ENDOCRINE-RELATED CANCER, 2004, 11 (04) : 709 - 724
  • [50] The expression of sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer
    Kwabi-Addo, B
    Wang, JH
    Erdem, H
    Vaid, A
    Castro, P
    Ayala, G
    Ittmann, M
    [J]. CANCER RESEARCH, 2004, 64 (14) : 4728 - 4735